![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Online Pharmacy Urges FDA to Pull All Ranitidine Products
Online Pharmacy Urges FDA to Pull All Ranitidine Products
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
October 1, 2019
An online pharmacy petitioned the FDA to recall and suspend the sale of all ranitidine-containing products in the U.S., raising alarms after its tests of the drug detected high levels of N-Nitrosodimethylamine (NDMA) across multiple manufacturers and dosage forms.
Valisure, a New Haven, Connecticut-based company that tests the medications it sells, said it found “extremely high levels” of NDMA in every ranitidine lot it tested.
The FDA daily intake limit for NDMA is just 96 nanograms for the probable human carcinogen. The company claimed that it detected levels in excess of 3 million nanograms per tablet.
Upcoming Events
-
21Oct